********DTOX NEWS*************
biz.yahoo.com
Thursday November 2, 7:31 am Eastern Time
Press Release
CITA Biomedical Receives U.S. Patent for Ultra-Rapid Opiate Detoxification
UROD Treatment Significantly Reduces Detoxification Process Time and Increases Comfort Level for Patients to More Easily Overcome Drug Addition
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Nov. 2, 2000-- CITA Biomedical Inc. (OTCBB:DTOX - news) a growing leader in the treatment of opiate dependency, today announced that it has received a U.S. patent for its successful UROD(SM) (Ultra Rapid Opiate Detoxification) treatment.
UROD(SM) is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin -- within four to six hours with few if any withdrawal symptoms.
``Backed by years of research and proven clinical experience, only CITA uses the safest, most sophisticated, rigorously tested medical procedures and highly competent medical staff,'' said Joseph Dunn, president and CEO of CITA Biomedical.
``We feel that some other companies that offer rapid opiate detoxification treatment may be infringing on the UROD(SM) patent, which could lead to improper administration and may be detrimental to patients. We intend to swiftly pursue the enforcement of our UROD(SM) patent rights, to ensure that the treatment remains safe and effective for all patients.''
Performed by CITA- and state-board certified physicians in CITA-licensed treatment centers, the UROD(SM) process is designed to purge opiates from the body with its unique pharmaceutical formula of FDA-approved medications.
Rather than cushioning the opiate addict from withdrawal pain by substituting another addictive drug, such as methadone, UROD treats the disease at the brain receptor level. By inhibiting all external opiate substitutes, UROD encourages the brain to resume producing its natural endorphins.
The treatment provides a safe and humane detoxification approach for patients, making it a far less painful recovery process than currently offered alternatives. This approach significantly enhances motivation for individuals who wish to overcome addiction.
``The UROD(SM) process produces superior results compared to other known method of treatment,'' said Dunn. ``Follow-up research has shown that after time periods of both six months and one year, more than 60 percent of our clients continue to lead opiate-free lives. This is a remarkable 300 percent improvement over the collective historical average of 15 percent for other treatment methods.''
CITA also offers a comprehensive aftercare program -- FIT(SM) (Flexible Intensity Treatment). After the UROD procedure, the patient embarks on a six-month medication and therapy regimen. The aftercare medication works by blocking opiate receptors in the central nervous system, allowing for continued repair and regeneration.
Unlike alternative processes, the medication used in the FIT process is not a substitute for heroin or other opiates, and creates no further dependency. In fact, while on the aftercare medication, if a patient uses opiates, the euphoric ``high'' is not experienced.
In addition to general therapy-related services, a key component of its continuing care program is www.CubeCentral.com. -- CITA's Web-based community portal. The portal was created to provide a host of products, support and services designed to aid addicts and recovering addicts, as well as family, friends and professionals, who may be affected by addiction and addiction recovery.
By channeling the talents of its core team of physicians, scientists and psychologists in a cooperative effort to advance the treatment of addiction, CITA Biomedical plans to remain on the forefront of advanced life-giving treatments for addiction.
About CITA Americas
CITA Americas Inc., with headquarters in Beverly Hills, Calif., is a wholly owned subsidiary of CITA Biomedical Inc. UROD is available at licensed treatment centers, including Los Angeles, Phoenix, Denver, Chicago and Portland, Ore. For more information, visit www.cita1.com.
About CITA Biomedical
CITA Biomedical Inc., with headquarters in Beverly Hills, Calif., focuses on investigation and treatment of addiction. The company grows its business through internal expansion and seeks compatible, competitive and complementing technologies and acquisitions to enhance its corporate portfolio. Other services include CITA's continuous treatment program, Flexible Intensive Therapy (FIT). CITA Biomedical Inc. has two operating divisions CITA Americas Inc. and CubeCentral.com Inc. For more information, visit www.citabio.com.
UROD and FIT are service marks of CITA Biomedical Inc.
The information contained in this news release includes forward-looking statements. Forward-looking statements include declarations concerning plans, objectives, goals, strategies, future events and/or performance, and underlying assumptions and other statements which are other than statements of historical facts. Forward-looking statements usually contain the words ``estimate,'' ``anticipate,'' ``believe,'' ``expect'' and other similar expressions that involve risks and uncertainties. These risks and uncertainties include, but are not limited to, the company's status as a start-up enterprise with uncertain profitability, its need for significant capital, limited facilities, competition, uncertainty as to market acceptance of its services, and the protection of its intellectual property. The company's actual results could differ materially from those expressed or implied in any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Communications on TAP for CITA Biomedical Inc.
Terri Powell, 408/241-0928
tpowell@comm-ontap.com
Investor Relations: 310/550-4971 |
